标题
The safety of daclatasvir for the treatment of hepatitis C
作者
关键词
-
出版物
Expert Opinion On Drug Safety
Volume 14, Issue 11, Pages 1787-1797
出版商
Informa Healthcare
发表日期
2015-11-17
DOI
10.1517/14740338.2015.1100603
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Daclatasvir in Combination With Asunaprevir and Beclabuvir for Hepatitis C Virus Genotype 1 Infection With Compensated Cirrhosis
- (2015) Andrew J. Muir et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
- (2015) Fred Poordad et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of Daclatasvir Resistance Barriers on NS5A from Hepatitis C Virus Genotypes 1 to 6: Implications for Cross-Genotype Activity
- (2014) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Daclatasvir + Asunaprevir: First Global Approval
- (2014) Raewyn M. Poole DRUGS
- New Hepatitis C Therapies: The Toolbox, Strategies, and Challenges
- (2014) Jean–Michel Pawlotsky GASTROENTEROLOGY
- Daclatasvir-Like Inhibitors of NS5A Block Early Biogenesis of Hepatitis C Virus–Induced Membranous Replication Factories, Independent of RNA Replication
- (2014) Carola Berger et al. GASTROENTEROLOGY
- Kinetic Analyses Reveal Potent and Early Blockade of Hepatitis C Virus Assembly by NS5A Inhibitors
- (2014) David R. McGivern et al. GASTROENTEROLOGY
- Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection
- (2014) Hiromitsu Kumada et al. HEPATOLOGY
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
- (2014) Jordan J. Feld et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
- (2014) Nezam Afdhal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
- (2014) Kris V. Kowdley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV
- (2014) Peter Ferenci et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection
- (2014) Mark S. Sulkowski et al. NEW ENGLAND JOURNAL OF MEDICINE
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
- (2014) Fred Poordad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Persistence of Resistant Variants in Hepatitis C Virus-Infected Patients Treated with the NS5A Replication Complex Inhibitor Daclatasvir
- (2013) Chunfu Wang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate
- (2013) Marc Bifano et al. ANTIVIRAL THERAPY
- Review of direct-acting antiviral agents for the treatment of chronic hepatitis C
- (2013) Nihar Shah et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Selection of Resistant–Associated Variants to the NS5A Inhibitor Daclatasvir: Revenge of the Hepatitis C Virus
- (2013) Alessio Aghemo et al. GASTROENTEROLOGY
- Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir
- (2013) Fiona McPhee et al. HEPATOLOGY
- Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration
- (2013) R. Ke et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- 1203 SAFETY PROFILE OF DACLATASVIR IN COMBINATION WITH PEGINTERFERON alfa AND RIBAVIRIN IN 1100 PATIENTS WITH CHRONIC HCV INFECTION TREATED IN PHASE 2 STUDIES
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- 1413 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR TREATMENT OF CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-2, A PHASE III TRIAL
- (2013) M. Manns et al. JOURNAL OF HEPATOLOGY
- 1425 SIMEPREVIR (TMC435) WITH PEGINTERFERON/RIBAVIRIN FOR CHRONIC HCV GENOTYPE-1 INFECTION IN TREATMENT-NAÏVE PATIENTS: RESULTS FROM QUEST-1, A PHASE III TRIAL
- (2013) I. Jacobson et al. JOURNAL OF HEPATOLOGY
- Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders
- (2013) Anna S. Lok et al. JOURNAL OF HEPATOLOGY
- Interferon free therapy with direct acting antivirals for HCV
- (2013) Tarik Asselah et al. LIVER INTERNATIONAL
- HCV direct-acting antiviral agents: the best interferon-free combinations
- (2013) Raymond Schinazi et al. LIVER INTERNATIONAL
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence
- (2012) Khayriyyah Mohd Hanafiah et al. HEPATOLOGY
- Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
- (2012) Yoshiyasu Karino et al. JOURNAL OF HEPATOLOGY
- Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options
- (2012) Yoshiyuki Suzuki et al. JOURNAL OF HEPATOLOGY
- Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial
- (2012) Stanislas Pol et al. LANCET INFECTIOUS DISEASES
- Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein
- (2012) Oscar Belda et al. VIRUS RESEARCH
- Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1
- (2011) Richard E. Nettles et al. HEPATOLOGY
- Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in Humans: In Vitro and In Vivo Correlations
- (2011) Robert A. Fridell et al. HEPATOLOGY
- Distinct Functions of NS5A in Hepatitis C Virus RNA Replication Uncovered by Studies with the NS5A Inhibitor BMS-790052
- (2011) R. A. Fridell et al. JOURNAL OF VIROLOGY
- A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt
- (2011) William Sievert et al. LIVER INTERNATIONAL
- The global health burden of hepatitis C virus infection
- (2011) Francesco Negro et al. LIVER INTERNATIONAL
- A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel
- (2011) Markus Cornberg et al. LIVER INTERNATIONAL
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
- (2011) Ira M. Jacobson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein
- (2011) Choongho Lee et al. VIROLOGY
- Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
- (2010) Min Gao et al. NATURE
- Review: New direct-acting antivirals in the development for hepatitis C virus infection
- (2010) Paul J. Pockros Therapeutic Advances in Gastroenterology
- Synthesis and SAR of piperazinyl-N-phenylbenzamides as inhibitors of hepatitis C virus RNA replication in cell culture
- (2009) Immacolata Conte et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Diagnosis, management, and treatment of hepatitis C: An update
- (2008) Marc G. Ghany et al. HEPATOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now